Skip to content
Company Analysis

BioNexus Gene Lab Corp BGLC

A comprehensive view of key metrics, scores, and financial health for BioNexus Gene Lab Corp

Overview of BioNexus Gene Lab Corp.

BGLC NCM
Basic Materials Specialty Chemicals Micro Cap
BioNexus Gene Lab Corp. (BGLC), is a Micro Cap company, in the Specialty Chemicals industry, last closed at $2.24, about 112.1% undervalued vs fair value, -27.5% 1Y return, ranked 246/263 in sector.
$2.24
0.45%
As of March 13, 2026
Previous close • Vol 90d: 70.0%
52-Week Range
Market Cap
$5.29M
Enterprise Value
$4.33M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for BioNexus Gene Lab Corp.

Top Beats

Quick Facts

Website https://www.bionexusgenelab.co...
HQ Kuala Lumpur
Employees 30
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$4
$5
$6
Current: $2.24 +112% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$9.5M
-2.7%%
Gross Profit
$1.3M
-3%%
Operating Income
$-2.0M
36.5%%
Net Income
$-1.6M
39.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
154.0%
Excellent

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating BioNexus Gene Lab Corp's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
18
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
17
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 91% Coverage
Trade-Off Triangle Visualization A ternary plot showing BGLC's balance between Growth (43.6%), Profitability (17.5%), and Safety (39.0%). Growth 44% Safety 39% Profitability 17%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

41th percentile vs peers
41
Key Signals
EPS Growth YoY 45.8% 78p Rev Growth YoY -2.7% 49p Revenue CAGR 3Y -10.7% 17p TSR -99.0% 2p
Strengths
  • Current Ratio in top 20% of peers (3.81, 82th percentile)
  • Quick Ratio in top 20% of peers (3.10, 83th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

16th percentile vs peers
16
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

36th percentile vs peers
37
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for BioNexus Gene Lab Corp.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$4.75
- - -
+112.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info